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Research in Context Panel: 
Evidence before this study: Preclinical data, epidemiological studies, and meta-analyses of randomised 
data from cardiovascular trials support the hypothesis that aspirin could be an effective adjuvant cancer 
therapy (Langley R, et al. Br J Cancer 2011;105(8):1107-13; Algra AM et al. Lancet Oncol 2012;13(5):518-
27 ). Globally, several phase III studies are ongoing to assess this, though debate continues about the 
safety profile of aspirin particularly after radical therapy for gastrointestinal malignancies.  
Added value of this study: The Add-Aspirin trial (encompassing 4 individually powered phase III studies in 
gastro-oesophageal, colorectal, prostate and breast cancer) is the largest of the ongoing trials and 
includes a pre-defined feasibility analysis to assess the acceptability of randomisation, tolerability and 
toxicity based on an open label run-in phase prior to double- blind randomisation.  The data show that 
aspirin is well tolerated after radical cancer therapy, acceptable to patients, and there is no evidence to 
suggest there is increased toxicity in the gastro-oesophageal cohort over other tumour-specific cohorts. 
Implications of all the available evidence: Aspirin is a low cost generic drug with the potential to have a 
large impact on cancer outcomes globally. Outcomes from gastro-oesophageal cancer remain poor and 
there is an imperative to complete recruitment to the ongoing trials as quickly as possible.  The rationale 
and supporting evidence for evaluating aspirin as a potential anti-cancer therapy remains strong. More 
generally, a run-in approach may be useful in adjuvant (or prevention) studies for reducing the risk of 
non-adherence and participant attrition at a later date. 
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ABSTRACT 
Background: Pre-clinical, epidemiological and randomised data indicate aspirin prevents tumour 
development and metastases leading to reduced cancer mortality, particularly for gastro-oesophageal and 
colorectal cancer.  Randomised trials evaluating aspirin use after primary radical therapy are ongoing. To 
address concerns about toxicity particularly bleeding after radical treatment for gastro-oesophageal 
cancer, a pre-planned feasibility analysis was incorporated into the ongoing Add-Aspirin trial. 
Method: The Add-Aspirin protocol includes 4 phase III randomised-controlled trials evaluating the effect 
of aspirin on recurrence/survival after radical therapy in 4 tumour cohorts: gastro-oesophageal (GO), 
colorectal (CRC), breast and prostate.  An open-label run-in phase (aspirin 100mg daily for 8 weeks) 
precedes double-blind randomisation (1:1:1 aspirin 300mg: aspirin 100mg: matched placebo). A pre-
planned analysis of feasibility, including recruitment, adherence, and toxicity was performed. The trial is 
registered with the International Standard Randomised Controlled Trials Number registry 
(ISRCTN74358648), and remains open to recruitment. 
Findings: After two years of recruitment (October 2015- October 2017), 3494 participants were registered 
on the trial (gastro-oesophageal 115, colorectal 950, breast 1675, prostate 754) with end of run-in data 
available for 2253. Adherence: 95% (2148/2253) took 6-7 tablets/week and 85% proceeded to 
randomisation, with rates consistent across tumour cohorts. 0·6% (14/2253) reported grade 3 toxicity 
during the run-in period, with no upper gastrointestinal bleeding (any grade) in the gastro-oesophageal 
cohort. The most frequent grade 1/2 toxicity overall was dyspepsia in 6.5% (146/2253).  
Interpretation: Aspirin is well-tolerated after radical cancer therapy though marked differences in 
recruitment rates across the tumour cohorts within the Add-Aspirin trial were seen. Toxicity has been low 
and there is no evidence of a difference in adherence, acceptance of randomisation or toxicity between 
the cohorts.  Aspirin offers a potential low cost and well tolerated therapy to improve gastrointestinal 
cancer outcomes. 
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Introduction 
Globally, cancers arising from the oesophagus, stomach and colon account for approximately 20% of all 
cancer mortality (1).  Mean five year survival rates from gastro-oesophageal cancer are particularly poor 
(15%) (2), attributed to the frequently advanced stage at presentation of the disease and the challenges 
of treatment (3). These factors are compounded in low and middle income countries by the lack of access 
to potentially curative therapies and treatment costs.  
Pre-clinical and observational studies provide substantial evidence that aspirin may prevent or delay the 
development of cancer and metastases (4, 5). Many observational studies have demonstrated an 
association between aspirin use and a decreased risk of developing cancer (3, 6), particularly for gastro-
oesophageal and colorectal cancer (Table 1).  For example, the relative risk (RR) of developing 
oesophageal cancer in aspirin users compared to non-users is estimated to be 0·75, 95% confidence 
interval (CI) 0·62-0·89 (7-9). Similar effects are seen for several other common cancers including gastric, 
colorectal, pancreatic, ovarian, breast and prostate cancer. Most recently an epidemiological study of 
63,605 patients who had received Helicobacter pylori eradication therapy reported a relative risk 
reduction of 70% in the development of gastric cancer with aspirin use (HR 0·30, 95% CI 0·15-0·61) (10). 
Meta-analyses of randomised-controlled trials (RCTs) designed to investigate the cardiovascular effects of 
aspirin support the observations that aspirin reduces the risk of developing cancer. Long-term follow up of 
approximately 77,000 trial participants demonstrates a reduced risk of fatal cancer in those allocated to 
aspirin compared to placebo (11, 12). The greatest effects were seen in oesophageal and colorectal 
cancer, with a reduction in the 20-year risk of death from oesophageal cancer of 58% (hazard ratio (HR) 
0·42, 95% CI 0·25-0·71, p=0·001) and for colorectal cancer death (HR 0·60, 95% CI 0·45-0·81, p=0·0007) 
(11, 13). Further analysis attributed the reduction in cancer mortality with aspirin to a reduction in the risk 
of metastases both at presentation (HR 0·69, 95% CI 0·38-0·77, p=0·0007) and subsequently (HR 0·45, 95% 
CI 0·28-0·72, p=0·0009).   
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Substantiating the hypothesis that aspirin reduces the risk of metastases several non-randomised cohort 
and population studies (also summarised in Table 1) demonstrate that aspirin use after a cancer diagnosis 
reduces both cancer mortality and overall mortality compared to non-use. For example, a recent Dutch 
population-based study of 13,000 patients with gastrointestinal cancer showed a marked reduction in 
overall mortality of 48% (HR 0·52, 95% CI 0·44-0·63) in aspirin users post diagnosis compared to non-users 
(14). Similarly, a study of more than 1700 patients in China who underwent surgical resection for gastro-
oesophageal cancer reported a five-year survival of 51·2% in those patients allocated to daily aspirin post-
operatively compared to only 41% on placebo (p=0·04) (15).  
Based on these studies, several large, long-term randomised trials are underway to assess the benefit of 
aspirin after radical cancer therapy. The largest and most comprehensive is the Add-Aspirin protocol 
(ISRCTN74358648), which encompasses individually powered phase III trials in 4 common tumours gastro-
oesophageal, colorectal, breast and prostate cancer. A pre-planned feasibility analysis (after two years of 
recruitment) was incorporated into the Add-Aspirin trial to assess recruitment, tolerability, and 
adherence, and to address any concerns about toxicity, particularly gastrointestinal bleeding, on aspirin 
after radical cancer therapy.  We present this analysis for all tumour cohorts to provide reassurance about 
the use of aspirin after radical cancer therapy.  
Method:  
Study Design and Participants: The Add-Aspirin protocol has been described in detail previously. In brief, 
the main eligibility criteria, across the four tumour cohorts, include completion of a standard radical 
potentially curable treatment schedule (which may include surgery +/- neoadjuvant or adjuvant 
oncological management or primary chemoradiation (CRT)), with no evidence of residual disease or 
metastases. Patients already receiving aspirin, other anti-coagulants or long-term non-steroidal anti-
inflammatory drugs are excluded. The gastro-oesophageal trial includes patients with histologically 
confirmed adenocarcinoma or squamous cell carcinomas of the oesophagus, gastro-oesophageal junction 
or stomach and the colorectal trial patients with adenocarcinomas stage II/III (and stage IV with 
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completely resected liver metastases only). Participants (in all cohorts) are over the age of 16, with no 
upper age limit, and have a performance status of 0-2. Exclusion criteria include evidence of 
moderate/severe renal impairment (glomerular filtration rate (eGFR) <45ml/min/1.73m2), and liver 
function tests greater than 1.5x the upper limit of normal. Participants with a history of active or previous 
peptic ulceration or gastrointestinal bleeding within the last year, except where the cause of bleeding has 
been surgically removed, are excluded. All participants provide fully informed written consent. 
Randomisation and masking: Randomisation is via a central system at the coordinating trials unit, 
accessible by phone to recruiting teams. Participants <75 years are randomised (1:1:1) to receive either 
aspirin 100mg, aspirin 300mg or a matched placebo to be taken daily for at least five years. Those aged 75 
years or older are randomised 2:1 to aspirin 100mg or matched placebo only, due to increased risks of 
toxicity with higher doses and older age (16). For both age groups, allocation uses a minimisation 
algorithm based on key prognostic factors (specific to tumour type and not listed here to protect the 
integrity of the ongoing trial) and incorporating a random element. Use of matching placebos and 
identical drug packs ensures that participants and investigators remain blind to treatment allocation. 
Procedures: Participants are initially registered onto the run-in phase of the study and receive aspirin 
100mg oral daily open-label for eight weeks. In the gastro-oesophageal cohort this can commence 
between six and fourteen weeks after surgery, up to fourteen weeks after the final fraction of 
radiotherapy, or up to eight weeks after the end of adjuvant chemotherapy, depending on which 
treatment pathway has been undertaken; and in the colorectal cohort timelines are slightly shorter, 
commencing six to twelve weeks after surgery and up to six weeks after the final fraction of adjuvant 
radiotherapy or end of adjuvant chemotherapy. Participants in the breast cohort may receive endocrine 
therapy and trastuzumab concomitant with trial participation where appropriate, and similarly androgen 
deprivation therapy in the prostate cohort may be ongoing at the time of trial registration.  
Dose reductions are not permitted in the run-in period; however time extensions are permitted if 
inadequate adherence is felt to be a temporary phenomenon. On completion of the run-in period, 
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adherence and tolerance of aspirin is assessed to determine suitability for subsequent randomisation. 
Participants experiencing any aspirin-related severe toxicity (grade ≥3 CTCAEv4), or significant (grade 3 or 
4) gastrointestinal bleed, active gastrointestinal ulceration, new or worsening tinnitus (≥ grade 2), macular 
degeneration, intracranial bleeding or hypersensitivity to aspirin do not proceed to randomisation. Early 
versions of the protocol considered any grade of gastrointestinal bleeding, rather than grade 3 or 4 only, 
an aspirin related severe toxicity, with the newer version of the protocol commenced in December 2016 
after 1,938 participants had already registered.  
Outcomes: The primary outcome measure for the colorectal, breast and prostate cohorts is based on 
disease recurrence and is overall survival for the gastro-oesophageal cohort. Secondary outcome 
measures include adherence, toxicity, second malignancies and cardiovascular events. The overall 
recruitment target for entry into the run-in phase is 11,000 participants from centres across the UK, India 
and the Republic of Ireland, although at the time of the feasibility analysis only UK sites had commenced 
recruitment.  
Statistical Analysis: The current analysis was based on recruitment rates, toxicity and adherence at the 
end of the run-in period, pre-planned two years after recruitment commenced. As a feasibility 
assessment, there was no comparative hypothesis nor associated power calculation. Analyses consisted of 
summary statistics (frequencies and percentages) based on data from the end of the run-in period 
including the proportion of participants proceeding to randomisation; tabulation of reasons for non-
randomisation; participant reported adherence and aspirin-related toxicities (reported using CTCAE v4) by 
grade and according to protocol requirements for treatment discontinuation. All participants for whom 
the relevant data had been received at the time of analysis were included. Analyses were conducted using 
Stata (StataCorp LLC, v.15).  
The Add-Aspirin trial (ISRCTN74358648, EudraCT 2013-004398-28) is being conducted in compliance with 
the Declaration of Helsinki 2008, the principles of Good Clinical Practice (GCP) and applicable national 
regulatory legislation.  The protocol was approved by the South Central – Oxford C research ethics 
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committee and by local Research and Development departments at all participating UK centres; as well as 
by local ethics committees at all participating Indian sites. All participants provided written informed 
consent before registration. All authors had access to the study data and reviewed and approved the final 
manuscript. The Add-Aspirin study is registered as an International Standard Randomised Controlled Trial 
[ISRCTN74358648].  
Role of the funding source: 
The academic study sponsor, University College London (UCL), through the team at the MRC Clinical Trials 
Unit at UCL, along with the multi-disciplinary Trial Management Group, had full responsibility for the 
study design, the collection, analysis, interpretation of data, writing of the report, and in the decision to 
submit the paper for publication. The trial statisticians (FHC, SR, KK) had full access to all the data in the 
study and corresponding author had final responsibility for the decision to submit for publication, in 
discussion with the independent data monitoring and trial steering committees.  
Results: 
Trial Recruitment: Recruitment commenced in October 2015 and, by October 2017, 3494 participants 
were registered from 150 centres across the UK (sites across India and the Republic of Ireland had yet to 
open to recruitment at the time of the feasibility analysis). The target registration rates were gastro-
oesophageal 2,350 in six years, colorectal 2,900 in three and a half years, breast 3,450 in three and a half 
years and prostate 2,350 in five years. Overall recruitment was good with registration rates exceeding the 
early estimated targets in the breast and prostate cohorts, but the gastro-oesophageal registrations in 
particular were slower than expected. At the time of the feasibility analysis, 115 were registered to the 
gastro-oesophageal cohort, 950 to the colorectal cohort, 1,675 to the breast cohort and 754 to the 
prostate cohort, with an average accrual rate of 167 registrations a month [Table 2]. Figure 1 shows the 
consort diagram for this analysis with end of run-in data available for 2253 participants at the time of the 
analysis. 
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Baseline Characteristics: Baseline characteristics of all participants from the breast, colorectal, gastro-
oesophageal and prostate cohorts were as expected [Table 3]. Median age was lowest in the breast 
participants (52 years), and highest in the prostate participants receiving radical radiotherapy (71 years). 
In the gastro-oesophageal cohort, participants were predominantly male (81%) and histology 
adenocarcinoma in 82% (68/83), with only 18% (15/83) squamous cell carcinoma. Most participants in the 
colorectal and gastro-oesophageal cohort were stage III (61% and 52% respectively). Most participants in 
the breast, colorectal and gastro-oesophageal cohorts had received chemotherapy, either neo-adjuvant, 
adjuvant or both. All gastro-oesophageal patients who have received radical surgery were mandated to 
use a proton pump inhibitor (PPI) with trial treatment and at the time of registration 11% of the breast 
cohort, 18% colorectal, 13% prostate and 69% of gastro-oesophageal patients were already prescribed 
PPIs [Table 3]. 
Randomisation: The run-in period was still ongoing in 300/3494 participants at the time of the feasibility 
analysis. Of those who had completed the run-in phase 2719/3194 (85%) had proceeded to 
randomisation. This rate was similar across all the tumour-specific cohorts and close to the 90% rate 
anticipated in the trial design. End of run-in data was available for 2253 participants (end-of run-in case 
report forms are received within two to eight weeks of completing the run-in). The reasons for not 
proceeding to randomisation were often multifactorial, with minor toxicity (grade 1-2) and/or patient 
choice most frequent [Figure 1 and Table 4]. 69/83 (83%) of gastro-oesophageal participants registered 
were treated with primary surgery. 60/69 (87%) received neoadjuvant and/ or adjuvant chemotherapy, 
and 618/710 (87%) of the colorectal participants, with 30% of these still ongoing [Table 3]. Very few 
participants (1%, 26/2253 with end of run-in data available) experienced toxicity requiring protocol-
mandated discontinuation of trial treatment. 2/26 were subsequently randomised after clinical review: 
one case of grade 3 hypertension, as the elevated blood pressure returned to normal on subsequent 
measurement; and one case of grade 2 tinnitus, which was deemed pre-existing and not felt to be related 
to trial treatment. Within the gastro-oesophageal cohort, only two participants (3%) experienced toxicity 
requiring discontinuation, one with grade 3 oesophageal pain and one grade 2 rectal bleed. The protocol 
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has subsequently been amended to allow participants with minor bleeding or bruising (grade 1-2) during 
the run-in period to continue in the trial, at the discretion of the investigator. 
Adherence: Adherence was generally good with 95% (2148/2253) taking 6-7 tablets per week, similar 
across the four cohorts (70/75, 93% of the gastro-oesophageal cohort; 578/602, 96% of the colorectal 
cohort), assessed using patient self-reporting, review of used blister packs and diary cards. 
Toxicity: 13/2253 (0·6%) reported grade 3 toxicities during the run-in period and no grade >3 
gastrointestinal bleeds were reported [Table 5]. 26% (157/602) of colorectal participants were receiving 
ongoing chemotherapy at the time of toxicity, and 17% of gastro-oesophageal. With the exception of the 
one participant experiencing grade 3 oesophageal pain, no other grade >3 toxicity occurred in the gastro-
oesophageal cohort. The most frequent grade 1 or 2 toxicity reported during the run-in period across all 
cohorts was dyspepsia (246/2253, 11%), with grade 1-2 bruising the second most frequent (211/2253, 
9%). Only one (1/602, 0·2%) participant experienced a grade 1 upper gastrointestinal bleed in the 
colorectal cohort, with no instances of upper gastrointestinal bleed of any grade in the gastro-
oesophageal cohort during the run-in period. 15/2253 (0.6%) of all participants experienced a grade 1-2 
lower gastrointestinal bleed, only one of which were in the gastro-oesophageal cohort. There were no 
grade 4 toxicities or treatment related deaths in any cohort. 
Discussion: 
The Add-Aspirin study is designed to assess the effect of aspirin on the prevention of metastases and 
disease recurrence following radical cancer therapy in high risk individuals. The data presented show 
aspirin is well tolerated after radical therapy including surgery or chemoradiation, acceptable to patients, 
and there is no early evidence of increased toxicity in patients who received radical therapy for gastro-
oesophageal cancer compared to the other common solid tumours within the Add-Aspirin protocol.  
The study has also demonstrated marked differences in recruitment rates across the 4 common cancers. 
Some of this variance is not unexpected. Gastro-oesophageal cancer, for example, is less common in high 
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income countries and fewer patients complete a radical treatment pathway. Shared risk factors with 
cardiovascular disease, particularly smoking, mean more potential participants are already prescribed 
aspirin and therefore ineligible for the study. However, the recruitment rates have been in line with 
predictions for the breast and prostate cohorts but below the anticipated rates in the gastro-oesophageal 
and colorectal cohorts, although the rationale for evaluating aspirin as a therapy to prevent recurrence is 
strongest for these tumour types. Long-term data from randomised vascular trials demonstrate that the 
greatest effect of aspirin in reducing cancer mortality was seen for gastrointestinal adenocarcinomas (20 
year risk of gastrointestinal cancer death HR 0·46, 95% CI 0·27-0·77, with benefits greatest for 
adenocarcinomas HR 0·66, 95% CI 0·56-0·77)(11). 
Recently reported randomised trials further support the rationale that aspirin prevents tumour 
development particularly in the gastrointestinal tract. In the phase III AspECT trial (NCT00357682) in 
Barrett’s metaplasia, the combination of a high dose proton pump inhibitor with 300mg of aspirin was 
demonstrated to significantly lengthen the time to event outcome, a composite of high grade dysplasia, 
oesophageal adenocarcinoma and all-cause mortality (17). Only 1% (28/2557) of participants experienced 
study-treatment-related grade 3-5 adverse events, of which only 0·6% (15/2557) were aspirin-related. 
Similarly, the SeAfOod trial (ISRCTN05926847) has shown a decrease in the mean number of colorectal 
adenomas per patient with allocation to aspirin (adjusted incidence rate ratio 0·78, 95% CI 0·68-0·90), 
particularly in right sided and serrated adenomas, and there was no increased risk of gastrointestinal 
adverse events in the aspirin group compared to placebo (18).  
In 2016, the US Preventative Task Force recommended initiating low dose aspirin for the primary 
prevention of cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 
10% or greater ten-year CVD risk, are not at increased risk for bleeding, and have a life expectancy of at 
least ten years(19). Despite this, concerns about the use of aspirin for cancer chemoprevention and the 
risk of serious bleeding continue (20). Aspirin does increase the risk of bleeding though the magnitude of 
this effect is often over-estimated. The most extensive randomised data from the Antithrombotic Trialists’ 
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Collaboration meta-analysis encompassing ~95,000 individuals demonstrated only a very modest increase 
in the risk of extracranial and major gastrointestinal bleeds from 0·07% per year to 0·1% per year on 
aspirin compared to control, with a similar small difference in the risk of intracranial bleeds (control 0·03% 
per year vs aspirin 0·04% per year, p=0·05) (21). No intracranial bleeds were reported during this 
feasibility analysis. The vast majority of bleeding episodes (excluding intracranial bleeding) related to 
aspirin resolve without sequelae (20), and in the vascular setting are generally considered to be 
outweighed by the benefits gained from aspirin, namely the prevention of secondary CVD events. From a 
population perspective, Cuzick et al have estimated that for every 100 men or women who start taking 
aspirin at the age of 55, over a 20 year period, the benefits on cancer mortality will be greater than on 
vascular mortality and outweigh the risks of serious bleeding (6). 
Reluctance to prescribe aspirin for cancer prevention has been highlighted in a recent study of UK general 
practitioners. Aspirin reduces the incidence of cancer in people with Lynch Syndrome and is 
recommended in several clinical guidelines, including The National Institute for Health and Care 
Excellence (NICE) (22). Despite this, a study of 1,007 UK general practitioners revealed that almost 20% 
were unwilling to prescribe 300mg of aspirin daily despite a randomised trial demonstrating its cancer 
preventative effects in Lynch Syndrome (23). More than 30% of respondents were uncomfortable 
discussing the benefits and harms of aspirin with their patients, even with the recommendation from a 
secondary care clinician (23).  This reluctance might partly explain the lower recruitment rates seen in the 
gastrointestinal cohorts of the Add-Aspirin study, particularly from physicians who treat patients with 
gastrointestinal bleeding. Several strategies are incorporated into the trial design to mitigate the bleeding 
risk on aspirin, including exclusion of individuals with a known increased risk of bleeding; randomising 
participants over the age of 75 years to only 100mg of aspirin or placebo (and not the higher aspirin 
dose), due to the increased risk of bleeding with both dose and age (16, 20); and use of a proton pump 
inhibitor for patients who have undergone gastrectomy or oesophagectomy, and recommended in those 
aged over 75 years (16).  The data presented in this paper should provide further reassurance that the risk 
to participants is low. 
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Completing recruitment within the predicted timelines remains a challenge for many clinical trials. 
Recruitment predictions from potential sites are used to advise trial recruitment projections, and sites 
have been shown to over-estimate their predicted recruitment rates based on their maximum or best 
possible, rather than mean monthly recruitment (24). When trials are slow to recruit, the relevance of the 
clinical question or the acceptability of the randomisation is frequently cited as the reason. The Add-
Aspirin protocol challenges these assumptions as the clinical question is the same across the tumour 
cohorts and there is no evidence that the randomisation is not acceptable to patients.  
Recent results published from the ASPREE (ASPirin in Reducing Events in the Elderly) trial (NCT01038583), 
which recruited more than 19,000 healthy participants mainly, >70 years old, who were randomly 
allocated to aspirin 100mg daily or placebo, showed no difference in the primary outcome measure (a 
composite of death, dementia and permanent physical disability)(25). Subgroup analyses reported an 
increase in cancer mortality, subsequently attributed to an increase in the risk of incident metastatic 
cancer but with no increase in incident cancers overall (26). Possible explanations for this observation 
include an increase in bleeding from occult metastatic disease in this older cohort unmasking some 
cancers at an earlier stage. The severity and consequences of bleeding with aspirin is known to increase 
with age (16, 20). Follow up of the ASPREE trial is currently relatively short at 4.7 years, and longer term 
follow-up may provide more clarification (25). Given the substantial body of previous data on the cancer 
chemopreventative effects of aspirin, the subgroup analysis from the ASPREE trial has not undermined 
the rationale for the Add-Aspirin trial or the other ongoing adjuvant aspirin studies internationally. 
Opportunities for combining data from these trials will exist in the future.    
To our knowledge, this is the most up-to-date and comprehensive data on the feasibility, toxicity and 
tolerability of aspirin use in breast, colorectal, prostate and gastro-oesophageal cancers after potentially 
curative therapy. One limitation to this study is that it is only relatively early data, but recent evidence 
suggests that the risk of bleeding events on aspirin reduces with time, most frequently occurring in the 
first few months of commencing treatment (16). As such, although only early data, it is likely to be a good 
15 
 
surrogate for the risk of future toxicity. More generally, since participants have all recently undergone 
major treatment, a significant amount of the reported toxicity in this study may be due to previous or 
ongoing other therapies. We also recognise that the measurements of adherence used are subject to 
recall bias, however translational sub-studies currently underway will also objectively measure adherence 
in this cohort of patients. Despite the challenging nature of radical therapy, particularly in the gastro-
oesophageal cohort where post-operative complication rates have been shown to be as high as 30% and 
have a major detrimental impact on quality of life (27), this has not been reflected in the measured 
adherence to trial treatment and, as a result, rates of progression from run-in to randomisation have been 
close to the expected 90% in line with the other cohorts.  
Conclusion 
The rationale and supporting evidence for evaluating aspirin as a potential anti-cancer therapy is strong 
and completion of clinical trials specifically designed to assess this hypothesis is the next required step. 
Re-purposed medicines such as aspirin offer the potential for low cost therapies to improve cancer 
outcomes. Evidence-based information about potential efficacy and toxicity is required to help physicians 
conduct meaningful discussions with potential participants about trial participation.  
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